• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Quoin Pharmaceuticals Ltd.

    10/27/25 4:32:22 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care
    Get the next $QNRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Quoin Pharmaceuticals Ltd.

    (Name of Issuer)


    Ordinary Shares, no par value per share

    (Title of Class of Securities)


    74907L409

    (CUSIP Number)


    10/20/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74907L409


    1Names of Reporting Persons

    Integrated Core Strategies (US) LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,901,585.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,901,585.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,901,585.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    74907L409


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,901,585.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,901,585.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,901,585.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    74907L409


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,901,585.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,901,585.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,901,585.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    74907L409


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,901,585.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,901,585.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,901,585.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Quoin Pharmaceuticals Ltd.
    (b)Address of issuer's principal executive offices:

    42127 Pleasant Forest Court, Ashburn, Virginia 20148-7349
    Item 2. 
    (a)Name of person filing:

    Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Ordinary Shares, no par value per share
    (e)CUSIP No.:

    74907L409
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page. The percent of class was calculated based on 21,116,150 Ordinary Shares outstanding as of October 14, 2025, which is the sum of (i) 20,585,830 Ordinary Shares outstanding as of August 6, 2025, as disclosed in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 7, 2025, and (ii) 530,320 Ordinary Shares (underlying 15,152 American Depositary Shares) sold pursuant to a private placement which closed on October 14, 2025, as disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on October 15, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Integrated Core Strategies (US) LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:10/24/2025
     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:10/24/2025
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:10/24/2025
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:10/24/2025

    Comments accompanying signature:  ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner CUSIP number 74907L409 has been assigned to the Issuer's American Depositary Shares. Each American Depositary Share represents thirty-five Ordinary Shares. No CUSIP number has been assigned to the Issuer's Ordinary Shares.
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of October 24, 2025, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $QNRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QNRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QNRX
    SEC Filings

    View All

    Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    11/17/25 5:00:56 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    11/12/25 8:00:51 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by Quoin Pharmaceuticals Ltd.

    S-3 - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

    11/7/25 4:46:05 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

    Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic Malformations and Venous Malformations, among others to Commence 1H 2026      ASHBURN, Va., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the target loading concentrations for its two topical rapamycin delivery technologies have been successfully achieved. Spe

    11/11/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results

    – Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to QRX003 for Netherton Syndrome  – Pediatric Netherton Clinical Program Expanded Based on Positive Long-Term Safety and Efficacy Data – QRX003 Pivotal Studies to Commence Enrollment in Q4 2025 – NETHERTON NOW Awareness Campaign Videos Achieve Over 1.5 Million Views in 6 Months Since Launch. – Positive Peeling Skin Data and Study Expansion Plans Released ASHBURN, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "

    11/6/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025

    ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights for the third quarter ended September 30, 2025, before the market opens on Thursday, November 6, 2025. About Quoin Pharmaceuticals Ltd.Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are c

    10/30/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Langer Dennis bought $128,640 worth of ADSs (15,152 units at $8.49), increasing direct ownership by 1,515,200% to 15,153 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    10/15/25 5:15:20 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    12/27/24 5:17:23 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    12/27/24 5:16:51 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Langer Dennis bought $128,640 worth of ADSs (15,152 units at $8.49), increasing direct ownership by 1,515,200% to 15,153 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    10/15/25 5:15:20 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    New insider Lawlor Sally Bridget claimed ownership of 440 units of ADS (SEC Form 3)

    3 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    9/8/25 4:31:14 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Leong Natalie Ee Mun

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    8/25/25 4:06:33 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Leadership Updates

    Live Leadership Updates

    View All

    Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

    ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting fir

    8/18/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Financials

    Live finance-specific insights

    View All

    Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update

    -  Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study -  FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome -  Initial Positive Data Announced from Peeling Skin Syndrome Pediatric Study -  Orphan Drug Designation Granted by European Medicines Agency for QRX003 -  Rare Pediatric Disease Designation Awarded by U.S. FDA -  NETHERTON NOW Campaign Expanded with New Patient and Expert Video Releases ASHBURN, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases provided a corporate upda

    8/7/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

    Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline GrowthLaunch of NETHERTON NOW Advocacy Initiative ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the quarter ended March 31, 2025. Quoin CEO Dr. Michael Myers

    5/13/25 8:00:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

    Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management Team ASHBURN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and nine months ended Sept. 30, 2024. Quoin CEO Dr. Michael Myers said, "The third quarter has been marked by notable achievements, including expanding the c

    11/7/24 8:00:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $QNRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    2/13/24 8:11:42 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    2/14/23 2:40:46 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care